Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Sublingual buprenorphine/naloxone (Bup/Nx) is approved for addiction treatment and may be useful for pain management, particularly in opioid-treated patients with pain with nonadherence behaviors. The transition of opioid-treated patients with pain to buprenorphine carries the risk of precipitated withdrawal and increased pain. This study convened pain and addiction specialists to develop and pilot a clinical protocol for safe transitioning to Bup/Nx. Design: The protocol was revised three times based on outside expert review and pilot study observations. The pilot was conducted with a prospective cohort of 12 patients with moderate to severe chronic pain, who were receiving long-term opioid therapy with any full µ-agonist drug, and had exhibited one or more aberrant drugrelated behaviors. Patients were followed up for 3-6 months with the expectation that they would experience few adverse events (AEs) and report lower pain severity. Results: The three patients on the highest baseline opioid dose (equivalent to 303-450 mg of oral morphine) and the three on the lowest doses (=20 mg) had early AEs when switched to Bup/Nx and did not complete the trial. Of the remaining six, one withdrew due to AEs; one responded well, then withdrew; and four completed a 3-month trial. A mixed-effects model controlling for dropouts found that average and worst pain significantly decreased after the switch to Bup/Nx (both p < 0.01). Conclusion: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing. Keywords: buprenorphine, chronic pain, treatment guidelines, opioid therapy, withdrawal DOI:10.5055/jom.2012.0137
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of the Current Opioid Misuse Measure
Butler, S. F., Budman, S. H., Fernandez, K. C., Houle, B., Benoit, C., Katz, N., & Jamison, R. N. (2007) · Pain · doi:10.1016/j.pain.2007.01.014 · Cited by 651
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Sublingual Buprenorphine Is Effective in the Treatment of Chronic Pain Syndrome
Malinoff, H. L., Barkin, R. L., & Wilson, G. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000160935.62883.ff · Cited by 121
Blondell, R. D., Ashrafioun, L., Dambra, C. M., Foschio, E. M., Zielinski, A. L., & Salcedo, D. M. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181ba895d · Cited by 59
Cited by
A review: Fentanyl and non-pharmaceutical fentanyls
Suzuki, J., & El-Haddad, S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.033 · Cited by 445
Frank, J. W., Lovejoy, T. I., Becker, W. C., Morasco, B. J., Koenig, C. J., Hoffecker, L., Dischinger, H. R., Dobscha, S. K., & Krebs, E. E. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0598 · Cited by 318
“Poor Studies will be graded “poor” if any of the following major limitations exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessme…”
BackgroundInfluentialTreating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
Avery, N., McNeilage, A. G., Stanaway, F., Ashton-James, C. E., Blyth, F. M., Martin, R., Gholamrezaei, A., & Glare, P. (2022) · BMJ · doi:10.1136/bmj-2021-066375 · Cited by 56
Dunn, K. E., Finan, P. H., Tompkins, D. A., Fingerhood, M., & Strain, E. C. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.10.018 · Cited by 50
Self-citation
Metadata
- Authors
- Rosenblum, P., Cruciani, M., Strain, M., Cleland, P., Joseph, P., Magura, P., Marsch, P., McNicholas, M., Savage, M., Sundaram, B., & Portenoy, M.
- Venue
- Journal of Opioid Management
- Publisher
- Weston Medical Publishing
- Published
- 2012-11-01
- Volume
- 8
- Issue
- 6
- Pages
- 369-382
- ISSN
- 1551-7489 (ISSN-L)
- DOI
- 10.5055/14
- OpenAlex
- W2035883503
- Cited by
- 51
- References
- 6
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.